Duration of antiviral immunity after smallpox vaccination
- PMID: 12925846
- DOI: 10.1038/nm917
Duration of antiviral immunity after smallpox vaccination
Abstract
Although naturally occurring smallpox was eliminated through the efforts of the World Health Organization Global Eradication Program, it remains possible that smallpox could be intentionally released. Here we examine the magnitude and duration of antiviral immunity induced by one or more smallpox vaccinations. We found that more than 90% of volunteers vaccinated 25-75 years ago still maintain substantial humoral or cellular immunity (or both) against vaccinia, the virus used to vaccinate against smallpox. Antiviral antibody responses remained stable between 1-75 years after vaccination, whereas antiviral T-cell responses declined slowly, with a half-life of 8-15 years. If these levels of immunity are considered to be at least partially protective, then the morbidity and mortality associated with an intentional smallpox outbreak would be substantially reduced because of pre-existing immunity in a large number of previously vaccinated individuals.
Comment in
-
Keeping the lock on smallpox.Nat Med. 2003 Sep;9(9):1115-6. doi: 10.1038/nm0903-1115. Nat Med. 2003. PMID: 12949522 No abstract available.
Similar articles
-
Antiviral immunity following smallpox virus infection: a case-control study.J Virol. 2010 Dec;84(24):12754-60. doi: 10.1128/JVI.01763-10. Epub 2010 Oct 6. J Virol. 2010. PMID: 20926574 Free PMC article.
-
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.J Infect Dis. 2004 Oct 1;190(7):1286-94. doi: 10.1086/423848. Epub 2004 Aug 30. J Infect Dis. 2004. PMID: 15346340 Clinical Trial.
-
The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.Clin Microbiol Infect. 2007 Jan;13(1):91-3. doi: 10.1111/j.1469-0691.2006.01576.x. Clin Microbiol Infect. 2007. PMID: 17184294
-
Immunity and immunological memory following smallpox vaccination.Immunol Rev. 2006 Jun;211:320-37. doi: 10.1111/j.0105-2896.2006.00392.x. Immunol Rev. 2006. PMID: 16824139 Review.
-
Evidence for Residual Immunity to Smallpox After Vaccination and Implications for Re-emergence.Mil Med. 2019 Dec 1;184(11-12):e668-e679. doi: 10.1093/milmed/usz181. Mil Med. 2019. PMID: 31369103
Cited by
-
Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.iScience. 2024 Jun 4;27(7):110177. doi: 10.1016/j.isci.2024.110177. eCollection 2024 Jul 19. iScience. 2024. PMID: 38993669 Free PMC article.
-
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines.Front Immunol. 2016 May 19;7:195. doi: 10.3389/fimmu.2016.00195. eCollection 2016. Front Immunol. 2016. PMID: 27242800 Free PMC article. Review.
-
Age-Related Dynamics of Lung-Resident Memory CD8+ T Cells in the Age of COVID-19.Front Immunol. 2021 Mar 29;12:636118. doi: 10.3389/fimmu.2021.636118. eCollection 2021. Front Immunol. 2021. PMID: 33854506 Free PMC article. Review.
-
The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research.SLAS Technol. 2020 Dec;25(6):522-544. doi: 10.1177/2472630320950248. Epub 2020 Aug 18. SLAS Technol. 2020. PMID: 32808850 Free PMC article. Review.
-
[Treatment and prevention of monkeypox].Enferm Infecc Microbiol Clin. 2022 Sep 22. doi: 10.1016/j.eimc.2022.08.001. Online ahead of print. Enferm Infecc Microbiol Clin. 2022. PMID: 36249471 Free PMC article. Review. Spanish.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical